Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;65(3):792-804.
doi: 10.1111/epi.17860. Epub 2024 Jan 20.

The role of copy number variants in the genetic architecture of common familial epilepsies

Collaborators

The role of copy number variants in the genetic architecture of common familial epilepsies

Epi4K Consortium. Epilepsia. 2024 Mar.

Abstract

Objective: Copy number variants (CNVs) contribute to genetic risk and genetic etiology of both rare and common epilepsies. Whereas many studies have explored the role of CNVs in sporadic or severe cases, fewer have been done in familial generalized and focal epilepsies.

Methods: We analyzed exome sequence data from 267 multiplex families and 859 first-degree relative pairs with a diagnosis of genetic generalized epilepsies or nonacquired focal epilepsies to predict CNVs. Validation and segregation studies were performed using an orthogonal method when possible.

Results: We identified CNVs likely to contribute to epilepsy risk or etiology in the probands of 43 of 1116 (3.9%) families, including known recurrent CNVs (16p13.11 deletion, 15q13.3 deletion, 15q11.2 deletion, 16p11.2 duplication, 1q21.1 duplication, and 5-Mb duplication of 15q11q13). We also identified CNVs affecting monogenic epilepsy genes, including four families with CNVs disrupting the DEPDC5 gene, and a de novo deletion of HNRNPU in one affected individual from a multiplex family. Several large CNVs (>500 kb) of uncertain clinical significance were identified, including a deletion in 18q, a large duplication encompassing the SCN1A gene, and a 15q13.3 duplication (BP4-BP5).

Significance: The overall CNV landscape in common familial epilepsies is similar to that of sporadic epilepsies, with large recurrent deletions at 15q11, 15q13, and 16p13 contributing in 2.5%-3% of families. CNVs that interrupt known epilepsy genes and rare, large CNVs were also identified. Multiple etiologies were found in a subset of families, emphasizing the importance of genetic testing for multiple affected family members. Rare CNVs found in a single proband remain difficult to interpret and require larger cohorts to confirm their potential role in disease. Overall, our work indicates that CNVs contribute to the complex genetic architecture of familial generalized and focal epilepsies, supporting the role for clinical testing in affected individuals.

Keywords: CNV; deletion; focal epilepsy; generalized epilepsy; genetics.

PubMed Disclaimer

Conflict of interest statement

Samuel Berkovic has received grants from UCB Pharma, Eisai, SciGen; consulting fees from Praxis Precision Medicines, Sequiris; honoraria from Eisai; has a patent for SCN1A testing held by Bionomics Inc licensed to Athena Diagnostics and Genetics Technologies Ltd. Ingrid Scheffer has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline, BioMarin, Nutricia, Rogcon, Chiesi, Encoded Therapeutics, Knopp Biosciences and Xenon Pharmaceuticals; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, Chiesi, Liva Nova and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin and Eisai; has served as an investigator for Zogenix, Zynerba, Ultragenyx, GW Pharma, UCB, Eisai, Xenon Pharmaceuticals, Anavex Life Sciences, Ovid Therapeutics, Epigenyx, Encoded Therapeutics and Marinus; and has consulted for Zynerba Pharmaceuticals, Atheneum Partners, Ovid Therapeutics, Care Beyond Diagnosis, Epilepsy Consortium and UCB; and is a Non-Executive Director of Bellberry Ltd. She may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; has a patent for SCN1A testing held by Bionomics Inc and licensed to various diagnostic companies; has a patent molecular diagnostic/theranostic target for benign familial infantile epilepsy (BFIE) [PRRT2] 2011904493 & 2012900190 and PCT/AU2012/001321 (TECH ID:2012-009). Heather Mefford has received support from CURE Epilepsy and serves on the American Society of Human Genetics Board of Directors. Lynette Sadleir has received consulting fees from the Epilepsy Consortium, Zynerba; is an advisor to Eisai; and is treasurer for the New Zealand League Against Epilepsy. Evan Eichler is a scientific advisory board member of Variant Bio, Inc.

Figures

Figure 1:
Figure 1:
CNVs involving DEPDC5 (A) and SCN1A (B) presented in the UCSC Genome Browser (hg19). For DEPDC5, 3 families harbored a partial deletion (orange) and one a partial duplication (blue) of the gene. For SCN1A, the green bar represents the duplication encompassing all of SCN1A (green shading) and surrounding DNA, though it does not extend to SCN2A or SCN3A (red shading). Black bars indicate CNVs from the literature involving SCN2A and SCN3A. Extent of the colored bars indicate extent of the CNV.

References

    1. Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, Eichler EE, Epstein MP, Glauser T, Goldstein DB, Han Y, et al. (2013). De novo mutations in epileptic encephalopathies. Nature 501, 217–221. 10.1038/nature12439. - DOI - PMC - PubMed
    1. Euro E-RESC, Epilepsy Phenome/Genome P, and Epi KC (2014). De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet 95, 360–370. 10.1016/j.ajhg.2014.08.013. - DOI - PMC - PubMed
    1. Mullen SA, Berkovic SF, and Commission IG (2018). Genetic generalized epilepsies. Epilepsia 59, 1148–1153. 10.1111/epi.14042. - DOI - PubMed
    1. consortium EK, and Project EPG (2017). Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. Lancet Neurol 16, 135–143. 10.1016/S1474-4422(16)30359-3. - DOI - PubMed
    1. Epilepsies I.L.A.E.C.o.C. (2018). Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nat Commun 9, 5269. 10.1038/s41467-018-07524-z. - DOI - PMC - PubMed